About ACEA Biosciences
ACEA Biosciences is a company based in San Diego (United States) founded in 2002 was acquired by Agilent in September 2018. ACEA Biosciences has raised $37.89 million across 2 funding rounds from investors including Agilent, Qiming Venture Partners and Lilly Asia Ventures. The company has 5,968 employees as of December 31, 2021. ACEA Biosciences operates in a competitive market with competitors including Cytek Biosciences, Accuri Cytometers, Bioaffinity technologies, NanoFCM and Orflo, among others.
- Headquarter San Diego, United States
- Employees 5968 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ACEA Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of ACEA Biosciences
ACEA Biosciences has successfully raised a total of $37.89M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $7.89 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ACEA Biosciences
ACEA Biosciences has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Agilent, Qiming Venture Partners and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Diversified instruments are developed for scientific and laboratory management.
|
Locked | Locked | Locked |
Investor details for ACEA Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACEA Biosciences
Investment portfolio details for ACEA Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ACEA Biosciences
Detailed financials for ACEA Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acea Biosciences Comparisons
Peer comparison for ACEA Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ACEA Biosciences
ACEA Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytek Biosciences, Accuri Cytometers, Bioaffinity technologies, NanoFCM and Orflo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Advanced flow cytometry systems are manufactured for research applications.
|
|
| Locked | Locked | Locked |
Compact flow cytometers for cell analysis are developed and provided.
|
|
| Locked | Locked | Locked |
IVD platforms are developed to detect and target cancer cells.
|
|
| Locked | Locked | Locked |
Offers advanced tools for nanoparticle analysis in biotechnology and healthcare.
|
|
| Locked | Locked | Locked |
Instrumentation for cell and protein analysis is developed and marketed.
|
Detailed competitors of ACEA Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acea Biosciences
Complete news archive for ACEA Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACEA Biosciences
ACEA Biosciences was founded in 2002 and raised its 1st funding round 13 years after it was founded.
ACEA Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
ACEA Biosciences is a funded company, having raised a total of $37.89M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at ACEA Biosciences is 5,968.
Founded in 2002 in San Diego, United States, instruments for life science research are developed by ACEA Biosciences. Operations focus on non-invasive technologies, including xCELLigence Real-Time Cell Analysis systems that utilize gold microelectrodes for label-free cell-based assays in multiwell formats. Additionally, the NovoCyte Flow cytometer is marketed to support high-throughput flow cytometry in research settings.
ACEA Biosciences's top competitors include Cytek Biosciences, Bioaffinity technologies and Accuri Cytometers.
ACEA Biosciences has 3 investors. Key investors include Agilent, Qiming Venture Partners, and Lilly Asia Ventures.